ArticleAmerican journal of translational research2026
Improved nasal function and reduced recurrence after endoscopic sinus surgery combined with vidian neurectomy in allergic rhinitis with chronic rhinosinusitis.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo compare the clinical outcomes of endoscopic sinus surgery (ESS) combined with vidian neurectomy versus ESS alone in patients with allergic rhinitis and chronic rhinosinusitis, and to identify factors associated with postoperative recurrence.
methodsA total of 375 patients with allergic rhinitis and chronic rhinosinusitis treated between 2019 and 2024 were included in this study. Patients were grouped into either the ESS alone (conventional treatment group; n=194) or the ESS with vidian neurectomy (combined treatment group; n=181) groups based on their treatment protocols. Propensity score matching (PSM; 1:1) was applied to balance baseline characteristics. Perioperative metrics, including nasal function, inflammatory and immune markers, as well as symptom and quality-of-life scores were compared between the two groups. Recurrence within 12 months postoperatively was recorded. Multivariate logistic regression analysis was performed to identify independent risk factors for disease recurrence.
resultsAfter PSM, baseline characteristics were comparable between the two groups. Compared with the conventional treatment group, the combined treatment group showed a shorter operative time (median 34 vs 45 min, P<0.001) and lower postoperative nasal resistance (0.16 vs 0.21 Pa/(cm
conclusionThe addition of vidian neurectomy to ESS was associated with superior improvements in symptoms and nasal function, modulation of inflammatory responses, and a reduced 12-month recurrence rate. Preoperative IL-4, eosinophils, SNOT-22 score, and smoking status are closely associated with disease recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.